0001209191-18-041303.txt : 20180703 0001209191-18-041303.hdr.sgml : 20180703 20180703182253 ACCESSION NUMBER: 0001209191-18-041303 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180701 FILED AS OF DATE: 20180703 DATE AS OF CHANGE: 20180703 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Mulroy Michael H. CENTRAL INDEX KEY: 0001509725 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-12830 FILM NUMBER: 18938861 MAIL ADDRESS: STREET 1: 1300 N. KELLOGG DRIVE, SUITE D CITY: ANAHEIM STATE: CA ZIP: 92807 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BIOTIME INC CENTRAL INDEX KEY: 0000876343 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 943127919 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1010 ATLANTIC AVENUE STREET 2: SUITE 102 CITY: ALAMEDA STATE: CA ZIP: 94501 BUSINESS PHONE: 5105213390 MAIL ADDRESS: STREET 1: 1010 ATLANTIC AVENUE STREET 2: SUITE 102 CITY: ALAMEDA STATE: CA ZIP: 94501 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2018-07-01 0 0000876343 BIOTIME INC BTX 0001509725 Mulroy Michael H. 1010 ATLANTIC AVENUE SUITE 102 ALAMEDA CA 94501 1 0 0 0 Common Shares, no par value 32550 D Option to Purchase Common Shares 2.06 2018-07-01 4 A 0 40000 0.00 A 2023-06-30 Common Shares 40000 40000 D Option to Purchase Common Shares 3.15 2022-06-30 Common Shares 20000 20000 D Option to Purchase Common Shares 2.72 2021-06-30 Common Shares 20000 20000 D Option to Purchase Common Shares 3.57 2020-06-30 Common Shares 20000 20000 D Option to Purchase Common Shares 3.29 2019-10-03 Common Shares 20000 20000 D Will become exercisable on June 30, 2019, based upon continued service on the board of directors. Became exercisable in four equal quarterly installments after the date of grant on July 1, 2017. Became exercisable in four equal quarterly installments after the date of grant on July 1, 2016. Became exercisable in four equal quarterly installments after the date of grant on July 1, 2015. Became exercisable in four equal quarterly installments after the date of grant on October 4, 2014. /s/Michael H. Mulroy 2018-07-03